Scientists are continuing the search for new drugs, more effective combinations, and therapeutic regimens that are easier to follow.
Several vaccines are in preclinical development and in clinical trials.
This vaccine approach combines one vaccine with a second one intended to augment the immune response generated by the first. The two vaccines preferentially stimulate different parts of the immune system. Basic research is essential in order to understand HIV and how it causes disease, and, in turn, to develop new treatments and vaccines. A two-vaccine approach One vaccine, vCP205, is made from a weakened canarypox virus used as a carrier for specific HIV genes. The second vaccine, rgp120, is a genetically engineered copy of an HIV surface protein.